The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.

The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.

The present invention provides macrocyclic compounds useful as therapeutic agents of the formula:

##STR00001##

or a pharmaceutically acceptable salt, ester, N-oxide, or prodrug thereof, wherein T, R.sup.1, R.sup.2, R.sup.3, D, E, F, and G are as defined herein. More particularly, these compounds are useful as anti-infective, antiproliferative, anti-inflammatory and prokinetic agents.

The present invention provides macrocyclic compounds useful as therapeutic agents of the formula:

##STR00001##

or a pharmaceutically acceptable salt, ester, N-oxide, or prodrug thereof, wherein T, R.sup.1, R.sup.2, R.sup.3, D, E, F, and G are as defined herein. More particularly, these compounds are useful as anti-infective, antiproliferative, anti-inflammatory and prokinetic agents.

The present invention provides a method for determining the presence of a microorganism in a sample using an electrochemically active reporter, wherein the method comprises (a) contacting the sample with an electrochemically active reporter, wherein the electrochemically active reporter is a conjugate comprising a sugar moiety and a redox active reporter moiety that are covalently linked such that the covalent bond can be enzymatically cleaved in the presence of the microorganism by an enzyme expressed by the microorganism, wherein the redox active reporter moiety is selected from the group consisting of resorufin and compounds of formula (I) as defined herein, under conditions that allow enzymatic cleavage of the covalent bond between the sugar moiety and the redox active reporter moiety and reduction of the redox active report moiety in the presence of the microorganism; (b) electrochemically determining the released redox active reporter moiety; and (c) determining the presence of the microorganism and, optionally, number of the microorganisms in the sample based on the determined released redox active reporter moiety. Also encompassed are the electrochemically active reporters used in the described methods and their use for determination of the presence of microorganisms in a sample.

The present invention provides a method for determining the presence of a microorganism in a sample using an electrochemically active reporter, wherein the method comprises (a) contacting the sample with an electrochemically active reporter, wherein the electrochemically active reporter is a conjugate comprising a sugar moiety and a redox active reporter moiety that are covalently linked such that the covalent bond can be enzymatically cleaved in the presence of the microorganism by an enzyme expressed by the microorganism, wherein the redox active reporter moiety is selected from the group consisting of resorufin and compounds of formula (I) as defined herein, under conditions that allow enzymatic cleavage of the covalent bond between the sugar moiety and the redox active reporter moiety and reduction of the redox active report moiety in the presence of the microorganism; (b) electrochemically determining the released redox active reporter moiety; and (c) determining the presence of the microorganism and, optionally, number of the microorganisms in the sample based on the determined released redox active reporter moiety. Also encompassed are the electrochemically active reporters used in the described methods and their use for determination of the presence of microorganisms in a sample.

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.

A process for the preparation and isolation of crystalline miglustat without the use of a column chromatography or ion exchange purification. The crystalline miglustat has a high purity and a melting point of 128 C. and an endothermic peak is 133 C.

The present invention relates to a novel benzopyran derivative useful for preparing a drug for treating cancer, and more specifically, to a novel benzopyran derivative which is a micromolecule having a macrophage inhibitory effect and is useful for preparing a drug for cancer treatment. The drug particularly inhibits the differentiation of immune macrophages to stimulate the immune system, and thus is useful for treating immune-related cancers.